Ganesh Rau, MD
Ophthalmology · Jersey City, NJNPI 1174671291
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 536 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 536 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$1K
- Biotissue Holdings Inc.$803
- Novartis$791
- Glaukos Corporation$783
- plus $4K from 18 others
What the payments were for
- Food & beverage$10,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 64 | $1,949 |
| AbbVie(2 entities) | 81 | $1,569 |
| Sun Pharmaceutical Industries Inc. | 78 | $1,165 |
| Biotissue Holdings Inc. | 26 | $803 |
| Novartis | 74 | $791 |
| Glaukos Corporation | 7 | $783 |
| Oyster Point Pharma, Inc. | 50 | $706 |
| Tarsus Pharmaceuticals, Inc. | 20 | $616 |
| Sight Sciences, Inc. | 12 | $474 |
| Dompe US, Inc. | 23 | $402 |
| Alcon | 23 | $346 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $244 |
| Kala Pharmaceuticals, Inc. | 14 | $196 |
| Harrow Eye, LLC | 9 | $156 |
| Eyevance Pharmaceuticals LLC | 8 | $139 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $129 |
| Ocular Therapeutix, Inc. | 8 | $112 |
| Travere Therapeutics, Inc. | 5 | $95 |
| Johnson & Johnson Vision Care, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $30 |
| Coopervision Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Nova Eye, Inc. | 1 | $17 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$1,301
- Prokera$401
- AmnioGraft$401
- OMNI(R) SURGICAL SYSTEM (US)$347
- SION SURGICAL INSTRUMENT$347
- XDEMVY$326
- iDoseTR$303
- VUITY$295
- DURYSTA$245
- CEQUA$234
- iStent Infinite$192
- iStent inject W$172
- KXL System$172
- Photrexa$172
- iDose$166
- RESTASIS MULTIDOSE$133
- Oxervate$108
How this compares
$10,807 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $472,468 |
| RestasisCyclosporine | 314 | $366,221 |
| XiidraLifitegrast | 196 | $245,153 |
| CequaCyclosporine | 145 | $167,856 |
| Cyclosporine | 128 | $112,833 |
| TyrvayaVarenicline Tartrate | 70 | $88,457 |
| LumiganBimatoprost | 118 | $61,177 |
| MieboPerfluorohexyloctane/Pf | 64 | $56,790 |
| CombiganBrimonidine Tartrate/Timolol | 105 | $38,940 |
| VevyeCyclosporine | 22 | $19,067 |
| VyzultaLatanoprostene Bunod | 44 | $18,714 |
| Prednisolone Acetate | 406 | $13,731 |
| Restasis MultidoseCyclosporine | 15 | $13,231 |
| ZyletTobramycin/Lotepred Etab | 21 | $11,499 |
| Ketorolac Tromethamine | 336 | $11,395 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose | $1,569 | $479,569552 claims |
| Dompe US, Inc.Oxervate | $402 | $472,46813 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $1,949 | $320,657304 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,165 | $167,856145 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $706 | $88,45770 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet, Alrex, Lotemax Sm | $244 | $23,19758 claims |
| Harrow Eye, LLCVevye | $156 | $19,06722 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $139 | $4,45425 claims |
| AlconSimbrinza | $346 | $3,65618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Jersey City
- Scott WalsmanJersey City$93K
- Kunjal ModiJersey City$24K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.